The Cooperative Research Centre (CRC) for Mental Health undertakes research to identify and confirm biomarkers for the early detection and treatment of Alzheimer’s and Parkinson’s disease (Neurodegeneration Program) as well as Schizophrenia and depression (Psychoses Program).
These biomarkers could range from specific cells, proteins, genes or gene products through to hormones, or be subtle brain image changes detected through MRI or PET scanning.
Once confirmed, these biomarkers will greatly enhance the opportunities for:
- determining the likelihood of an individual developing these diseases
- diagnosing the disease in its early stages
- monitoring the progression of the disease and
- assessing responses to drug treatment.
Work will then be undertaken with the relevant health care professionals involved in the CRC ensuring that these discoveries and new approaches to treatment are translated into practical approaches and integrated into modern medical and health care practices.
This CRC research will enable early intervention in particular mental health disorders, helping delay the onset of these conditions, and also potentially reducing the severity of disease by helping deliver more effective treatments.
The willingness of researchers from diverse streams of science to come together, sharing their knowledge and expertise to tackle these mental health conditions, is a testament to their dedication and commitment to a better world through scientific excellence.